TY - JOUR
T1 - Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease
AU - Jain COS Consortium
AU - Moore, Ursula
AU - Gordish, Heather
AU - Diaz-Manera, Jordi
AU - James, Meredith K.
AU - Mayhew, Anna G.
AU - Guglieri, Michela
AU - Fernandez-Torron, Roberto
AU - Rufibach, Laura E.
AU - Feng, Jia
AU - Blamire, Andrew M.
AU - Carlier, Pierre G.
AU - Spuler, Simone
AU - Day, John W.
AU - Jones, Kristi J.
AU - Bharucha-Goebel, Diana X.
AU - Salort-Campana, Emmanuelle
AU - Pestronk, Alan
AU - Walter, Maggie C.
AU - Paradas, Carmen
AU - Stojkovic, Tanya
AU - Mori-Yoshimura, Madoka
AU - Bravver, Elena
AU - Pegoraro, Elena
AU - Lowes, Linda Pax
AU - Mendell, Jerry R.
AU - Bushby, Kate
AU - Straub, Volker
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2021/4
Y1 - 2021/4
N2 - This study aims to determine clinically relevant phenotypic differences between the two most common phenotypic classifications in dysferlinopathy, limb girdle muscular dystrophy R2 (LGMDR2) and Miyoshi myopathy (MMD1). LGMDR2 and MMD1 are reported to involve different muscles, with LGMDR2 showing predominant limb girdle weakness and MMD1 showing predominant distal lower limb weakness. We used heatmaps, regression analysis and principle component analysis of functional and Magnetic Resonance Imaging data to perform a cross-sectional review of the pattern of muscle involvement in 168 patients from the Jain Foundation's international Clinical Outcomes Study for Dysferlinopathy. We demonstrated that there is no clinically relevant difference in proximal vs distal involvement between diagnosis. There is a continuum of distal involvement at any given degree of proximal involvement and patients do not fall into discrete distally or proximally affected groups. There appeared to be geographical preference for a particular diagnosis, with MMD1 being more common in Japan and LGMDR2 in Europe and the USA. We conclude that the dysferlinopathies do not form two distinct phenotypic groups and therefore should not be split into separate cohorts of LGMDR2 and MM for the purposes of clinical management, enrolment in clinical trials or access to subsequent treatments.
AB - This study aims to determine clinically relevant phenotypic differences between the two most common phenotypic classifications in dysferlinopathy, limb girdle muscular dystrophy R2 (LGMDR2) and Miyoshi myopathy (MMD1). LGMDR2 and MMD1 are reported to involve different muscles, with LGMDR2 showing predominant limb girdle weakness and MMD1 showing predominant distal lower limb weakness. We used heatmaps, regression analysis and principle component analysis of functional and Magnetic Resonance Imaging data to perform a cross-sectional review of the pattern of muscle involvement in 168 patients from the Jain Foundation's international Clinical Outcomes Study for Dysferlinopathy. We demonstrated that there is no clinically relevant difference in proximal vs distal involvement between diagnosis. There is a continuum of distal involvement at any given degree of proximal involvement and patients do not fall into discrete distally or proximally affected groups. There appeared to be geographical preference for a particular diagnosis, with MMD1 being more common in Japan and LGMDR2 in Europe and the USA. We conclude that the dysferlinopathies do not form two distinct phenotypic groups and therefore should not be split into separate cohorts of LGMDR2 and MM for the purposes of clinical management, enrolment in clinical trials or access to subsequent treatments.
KW - [16] Clinical neurology examination
KW - [176] All neuromuscular disease
KW - [185] Muscle disease
KW - [21] Clinical trials methodology
KW - [54] Cohort study
UR - http://www.scopus.com/inward/record.url?scp=85101092677&partnerID=8YFLogxK
U2 - 10.1016/j.nmd.2021.01.009
DO - 10.1016/j.nmd.2021.01.009
M3 - Article
C2 - 33610434
AN - SCOPUS:85101092677
SN - 0960-8966
VL - 31
SP - 265
EP - 280
JO - Neuromuscular Disorders
JF - Neuromuscular Disorders
IS - 4
ER -